Farmas USA

velas 30 min a punto de irse a bullish ...

veremos si es suficiente para brincar o hace falta esperar al MACD de 60 min

EXEL

REGN

Tiene huevos la casa

https://www.cnbc.com/2018/05/10/cramer-vets-biotech-giants-biogen-celgene-gilead-and-regeneron.html?__source=yahoo%7Cfinance%7Cheadline%7Cstory%7C&par=yahoo&yptr=yahoo

por eso sube? por el payaso de Cramer?

ains ...

Puez zi!

SGYP

Trulance Launch Looks Positive from the Eyes of Canaccord

Modeling in deferred net sales into the equation, the analyst notes that the fourth quarter’s non-GAAP net sales totaled around $7.3 million, suggesting an 18% quarter-over-quarter sales jump. Newman asserts, “Furthermore, we see the flattish 1Q vs 4Q as due to the Medicare Part D doughnut hole as well as insurance deductibles, which was also observed for Linzess prescriptions. SGYP also indicated that Trulance was the only prescription brand for CIC and IBS-C to show positive total and new prescription volume growth, with total number of unique prescribers increasing by more than 20% Q/Q to 12,000 prescribers. We view this as a positive indicator for Trulance’s clinical differentiation from Linzess.”

Another big positive from Newman’s eyes: “debt restructuring lifts financial pressure” for the drug maker’s shares. The company’s credit facility is notably “flexible,” which means the company can access $25 million by June 30th, $25 million by September 30th, and $50 million by December 31st, without being obligated to do so. For 2018, the analyst continues to anticipate Synergy can achieve its $61 million revenue target in the covenants.

We would expect Synergy to make the best strategic decision to enhance shareholder value, which could involve an outright sale of the company, a US partnership, ex-US partnership, or other path forward.”

https://www.smarteranalyst.com/analyst-insights/healthcare-analyst-news/synergy-pharmaceuticals-sgyp-trulance-launch-looks-positive-eyes-canaccord/

Por el ritmo y volumen que lleva, debería de llegar a los 2$, luego ya veremos qué hace...

ADXS

SGYP

Del comunicado de prensa

In the nine weeks since the launch of the IBS-C indication in late February, TRULANCE prescription volume grew 24% versus the prior nine weeks or nearly five times the branded CIC and IBS-C prescription market growth rate, per IQVIA.

TRULANCE was the only prescription brand for CIC and IBS-C to show positive total and new prescription volume growth in the first quarter over the prior quarter, per IQVIA.

The total number of unique healthcare practitioners prescribing TRULANCE since launch reached nearly 12,000 in the first quarter of 2018, increasing more than 20% over the prior quarter, per IQVIA.

TRULANCE currently has over 70% payer coverage across all segments including commercial, Medicare Part D and Managed Medicaid.

Synergy's Canadian partner, Cipher Pharmaceuticals, is currently in discussions with Health Canada and plans to file a New Drug Submission for TRULANCE in IBS-C in the second half of 2018.

Y aquí las diapos:

https://78449.themediaframe.com/dataconf/productusers/synpharm/mediaframe/24038/indexl.html

SGYP
Yo me he salido en 1,63 en even comisiones incluidas. Esoero entrar mas abajo. Tengo orden a 1,55 pero no ha entrado.